Literature DB >> 10924701

Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole.

K Takata1, Y Kitamura, J Kakimura, Y Kohno, T Taniguchi.   

Abstract

Treatment of rats for 4 days with the antiparkinsonian drugs, talipexole and pramipexole, markedly increased Bcl-2 immunoreactivity in neuronal dendritic processes in both cerebral cortex and hippocampus, but treatment for 1 day with either of these drugs did not. Repeated administration of talipexole or pramipexole may have neuroprotective effect in neurodegenerative disorders.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10924701     DOI： 10.1016/s0006-8993(00)02493-8

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  7 in total

1.  Dopaminergic influences on emotional decision making in euthymic bipolar patients.

Authors:  Katherine E Burdick; Raphael J Braga; Chaya B Gopin; Anil K Malhotra
Journal:  Neuropsychopharmacology       Date:  2013-07-25       Impact factor: 7.853

Review 2.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

Authors:  Yoshihisa Kitamura; Takashi Taniguchi; Shun Shimohama; Akinori Akaike; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 4.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

Review 5.  Protection against Parkinson's disease progression: clinical experience.

Authors:  Peter A LeWitt; Danette C Taylor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.

Authors:  Jose A Franco-Chaves; Camilo F Mateus; David A Luckenbaugh; Pedro E Martinez; Alan G Mallinger; Carlos A Zarate
Journal:  J Affect Disord       Date:  2013-03-18       Impact factor: 4.839

Review 7.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.